Nelfinavir failure doesn't limit other protease inhibitors
Nelfinavir failure doesn't limit other protease inhibitors
Patients who have failed treatment with nelfinavir have been treated with other protease inhibitors and experienced favorable anti-HIV responses, reports its manufacturer, Agouron Pharmaceuticals of La Jolla, CA.
A study of 26 patients showed that 24 weeks after switching from nelfinavir, 68% of patients had viral loads below detection using bDNA assay. The patients were switched to a combination including ritonavir or saquinavir.
Agouron also reports preliminary results from clinical studies indicating that twice-daily dosing of nelfinavir produces anti-HIV effects comparable to those resulting from the standard three-times-daily dosing.
Studies have shown that combination therapy with nelfinavir can produce undetectable levels of virus in patients for more than 24 months.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.